FIRST CLICK HERE AND READ OUR OVERVIEW
At the International Conference in Boston recently Philip M Arlen, NCI MD talked about a combination of using docetaxel with a vaccine against PSA (prostate-specific antigen). The initial vaccination is followed up monthly. Treatment in the trial took 103 days.
All the patients in the trial had androgen-independent metastatic prostate cancer. Two of the twenty-six patients have had PSA declines exceeding 50 per cent.
The vaccine consists of a recombinant vaccinia virus that expresses the PSA gene, together with a recombinant virus that expresses the B7-1 gene.